Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ronan Swords

Showing results (1-10 of 59) with videos related to

Pageof 6
Sort By:
Hematology. American Society of Hematology. Education Program|December 13, 2012
In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?Ronan Swords, Valeria Santini
Medical Oncology (Northwood, London, England)|August 4, 2007
Hairy cell leukemiaRonan Swords, Francis Giles
Clinical Lymphoma & Myeloma|March 27, 2007
Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemiaRonan Swords, Yesid Alvarado, Francis Giles
Medical Oncology (Northwood, London, England)|August 4, 2007
Recent advances in the diagnosis and therapy of Richter's syndromeRonan Swords, John Bruzzi, Francis Giles
Hematology (Amsterdam, Netherlands)|July 4, 2007
Troxacitabine in leukemiaRonan Swords, Effrosyni Apostolidou, Francis Giles
Expert Opinion on Pharmacotherapy|May 22, 2013
Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?Ciara Freeman, Niamh Keane, Ronan Swords, et al.
Expert Review of Hematology|January 26, 2012
Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?Ciara L Freeman, Ronan Swords, Francis J Giles
American Journal of Hematology|January 8, 2025
Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous LeukemiaJohn T Butler, William M Yashar, Ronan Swords
Expert Opinion on Emerging Drugs|March 16, 2007
Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemiaYesid Alvarado, Effrosyni Apostolidou, Ronan Swords, et al.
Leukemia & Lymphoma|June 10, 2010
Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agentsKevin Kelly, Ronan Swords, Devalingam Mahalingam, et al.
Pageof 6

Showing results (1-10 of 59) with videos related to

Sort By:
Pageof 6
Hematology. American Society of Hematology. Education Program|December 13, 2012
In elderly patients with AML, which patients should be considered fit or unfit for standard induction therapy?Ronan Swords, Valeria Santini
Medical Oncology (Northwood, London, England)|August 4, 2007
Hairy cell leukemiaRonan Swords, Francis Giles
Clinical Lymphoma & Myeloma|March 27, 2007
Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemiaRonan Swords, Yesid Alvarado, Francis Giles
Medical Oncology (Northwood, London, England)|August 4, 2007
Recent advances in the diagnosis and therapy of Richter's syndromeRonan Swords, John Bruzzi, Francis Giles
Hematology (Amsterdam, Netherlands)|July 4, 2007
Troxacitabine in leukemiaRonan Swords, Effrosyni Apostolidou, Francis Giles
Expert Opinion on Pharmacotherapy|May 22, 2013
Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?Ciara Freeman, Niamh Keane, Ronan Swords, et al.
Expert Review of Hematology|January 26, 2012
Amonafide: a future in treatment of resistant and secondary acute myeloid leukemia?Ciara L Freeman, Ronan Swords, Francis J Giles
American Journal of Hematology|January 8, 2025
Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous LeukemiaJohn T Butler, William M Yashar, Ronan Swords
Expert Opinion on Emerging Drugs|March 16, 2007
Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemiaYesid Alvarado, Effrosyni Apostolidou, Ronan Swords, et al.
Leukemia & Lymphoma|June 10, 2010
Optimizing outcomes in patients with chronic myeloid leukemia in chronic phase: comparative safety profiles of newer agentsKevin Kelly, Ronan Swords, Devalingam Mahalingam, et al.
Pageof 6